Oral azacitidine, evaluated in the QUAZAR AML-001 trial [26], has demonstrated improved OS in post-remission settings and is now being explored in combination with venetoclax to extend remission duration in NPM1-mutated AML. The gene discussed is NPM1; the disease is acute myeloid leukemia.